1. Home
  2. Research
  3. Research Groups
  4. Rheumatology

Rheumatology

The group focuses its research projects on non-traumatic musculoskeletal diseases, mainly autoimmune diseases (Lupus, Scleroderma, Vasculitis, Inflammatory myopathies,...), and immune-mediated arthropathies (rheumatoid arthritis, psoriatic arthritis, spondyloarthritis,...). The group has mainly carried out clinical research studies (description of disease phenotypes, response to treatments) and, in recent years, basic research (histopathology, immunology, and genetics) has been added. Likewise, innovative projects have been developed (training of rheumatic patients, thermal imaging in arthritis, mobile devices for monitoring chronic diseases) for application to clinical practice. Four members of the group are doctors and 5 more are finishing their PhD. We have got updated records of disease groups, clinical situation and prescribed advanced (biological) treatments. We have got a collection of biological samples of all these autoimmune diseases in different stages of evolution and different treatments

Milestones

  1. Start of the joint research project "Towards Telemonitoring in Immune-mediated Inflammatory Diseases: Implementation of a Mixed Care Model (MAM) in a Complex Therapy Unit". (PI22/00777 Hospital Universitario La Paz.  PI: Alejandro Balsa Criado. 2023-2025).
  2. Collaboration with the Geriatrics group of area 5 of Irycis in the search for specific biomarkers in rheumatoid arthritis in the elderly.
  3. Publication of the book: "Basic musculoskeletal radiology in Rheumatology". ISBN:978-84-09-56324-1 Ed. Carlos de la Puente Bujidos. 2023. Publisher: Entheos
  4. 2023 Duncan A. Gordon Award to the article published by members of the group "Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases. J Rheumatol. 2021 Jul;48(7):1098-1102. doi: 10.3899/jrheum.200755. PMID: 33722949" awarded by the prestigious journal The Journal of Rheumatology as the best publication with the highest impact, originality and ability to improve clinical practice.
  5. Publication of a joint article in a high impact journal: Di Rocco M et al. Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Med. 2023 Sep 28. doi: 10.1038/s41591-023-02561-8